Last reviewed · How we verify

Remifentanil, Dexmedetomidine, and Desflurane

The Cooper Health System · FDA-approved active Small molecule

Remifentanil, Dexmedetomidine, and Desflurane is a General anesthetic combination Small molecule drug developed by The Cooper Health System. It is currently FDA-approved for General anesthesia for surgical procedures, Sedation and analgesia during anesthesia maintenance. Also known as: Ultiva, Suprane, Precedex.

This is a combination of three anesthetic agents that work synergistically: remifentanil (opioid agonist), dexmedetomidine (alpha-2 adrenergic agonist), and desflurane (volatile anesthetic) to produce sedation, analgesia, and unconsciousness for surgical procedures.

This is a combination of three anesthetic agents that work synergistically: remifentanil (opioid agonist), dexmedetomidine (alpha-2 adrenergic agonist), and desflurane (volatile anesthetic) to produce sedation, analgesia, and unconsciousness for surgical procedures. Used for General anesthesia for surgical procedures, Sedation and analgesia during anesthesia maintenance.

At a glance

Generic nameRemifentanil, Dexmedetomidine, and Desflurane
Also known asUltiva, Suprane, Precedex
SponsorThe Cooper Health System
Drug classGeneral anesthetic combination
TargetMu-opioid receptor (remifentanil), alpha-2 adrenergic receptor (dexmedetomidine), GABA and other CNS targets (desflurane)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Remifentanil binds to mu-opioid receptors to provide rapid-onset analgesia and sedation. Dexmedetomidine activates alpha-2 adrenergic receptors in the central nervous system to produce sedation and anxiolysis with preserved airway reflexes. Desflurane is a volatile anesthetic that enhances CNS depression and unconsciousness. Together, these agents provide balanced anesthesia with complementary mechanisms for induction and maintenance during surgery.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Remifentanil, Dexmedetomidine, and Desflurane

What is Remifentanil, Dexmedetomidine, and Desflurane?

Remifentanil, Dexmedetomidine, and Desflurane is a General anesthetic combination drug developed by The Cooper Health System, indicated for General anesthesia for surgical procedures, Sedation and analgesia during anesthesia maintenance.

How does Remifentanil, Dexmedetomidine, and Desflurane work?

This is a combination of three anesthetic agents that work synergistically: remifentanil (opioid agonist), dexmedetomidine (alpha-2 adrenergic agonist), and desflurane (volatile anesthetic) to produce sedation, analgesia, and unconsciousness for surgical procedures.

What is Remifentanil, Dexmedetomidine, and Desflurane used for?

Remifentanil, Dexmedetomidine, and Desflurane is indicated for General anesthesia for surgical procedures, Sedation and analgesia during anesthesia maintenance.

Who makes Remifentanil, Dexmedetomidine, and Desflurane?

Remifentanil, Dexmedetomidine, and Desflurane is developed and marketed by The Cooper Health System (see full The Cooper Health System pipeline at /company/the-cooper-health-system).

Is Remifentanil, Dexmedetomidine, and Desflurane also known as anything else?

Remifentanil, Dexmedetomidine, and Desflurane is also known as Ultiva, Suprane, Precedex.

What drug class is Remifentanil, Dexmedetomidine, and Desflurane in?

Remifentanil, Dexmedetomidine, and Desflurane belongs to the General anesthetic combination class. See all General anesthetic combination drugs at /class/general-anesthetic-combination.

What development phase is Remifentanil, Dexmedetomidine, and Desflurane in?

Remifentanil, Dexmedetomidine, and Desflurane is FDA-approved (marketed).

What are the side effects of Remifentanil, Dexmedetomidine, and Desflurane?

Common side effects of Remifentanil, Dexmedetomidine, and Desflurane include Hypotension, Bradycardia, Respiratory depression, Emergence delirium, Nausea and vomiting.

What does Remifentanil, Dexmedetomidine, and Desflurane target?

Remifentanil, Dexmedetomidine, and Desflurane targets Mu-opioid receptor (remifentanil), alpha-2 adrenergic receptor (dexmedetomidine), GABA and other CNS targets (desflurane) and is a General anesthetic combination.

Related